Is OVID or UNCY more profitable?

Ovid Therapeutics' return on equity of -23.64% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics N/A -23.64% -20.52% Unicycive Therapeutics N/A -91.50% -61.47%

Does the media favor SPRY or UNCY?

In the previous week, Unicycive Therapeutics had 17 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 21 mentions for ARS Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.26 beat ARS Pharmaceuticals' score of 0.11 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 19 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CGC or UNCY?

Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 327.90%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media prefer CGC or UNCY?

In the previous week, Unicycive Therapeutics had 17 more articles in the media than Canopy Growth. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 21 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.26 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 14 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 19 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVIR or UNCY more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Unicycive Therapeutics N/A -91.50% -61.47%

Unicycive Therapeutics (UNCY) Competitors

$4.22 -0.33 (-7.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.24 +0.02 (+0.55%)

As of 07:56 PM Eastern

Compare

UNCY vs. OVID, ASMB, SPRY, CGC, and AVIR

Should you buy Unicycive Therapeutics stock or one of its competitors? Unicycive Therapeutics's main competitors and comparable companies include Ovid Therapeutics (OVID), Assembly Biosciences (ASMB), ARS Pharmaceuticals (SPRY), Canopy Growth (CGC), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ovid Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 150.52%. Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 327.90%. Given Unicycive Therapeutics' higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Ovid Therapeutics' return on equity of -23.64% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Ovid Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.52	-$17.41M	-$0.31	N/A
Unicycive Therapeutics	$680K	174.68	-$26.56M	-$1.75	N/A

Ovid Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 38 more articles in the media than Ovid Therapeutics. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 0 mentions for Ovid Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.26 beat Ovid Therapeutics' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Unicycive Therapeutics	Neutral

Summary

Ovid Therapeutics beats Unicycive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Assembly Biosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market.

Unicycive Therapeutics has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

In the previous week, Unicycive Therapeutics had 38 more articles in the media than Assembly Biosciences. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 0 mentions for Assembly Biosciences. Unicycive Therapeutics' average media sentiment score of 0.26 beat Assembly Biosciences' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Neutral
Unicycive Therapeutics	Neutral

Assembly Biosciences has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.83
Unicycive Therapeutics	$680K	174.68	-$26.56M	-$1.75	N/A

Assembly Biosciences currently has a consensus price target of $47.50, indicating a potential upside of 113.34%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 327.90%. Given Unicycive Therapeutics' higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Unicycive Therapeutics beats Assembly Biosciences on 9 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Unicycive Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	4.97	-$171.30M	-$2.18	N/A
Unicycive Therapeutics	$680K	174.68	-$26.56M	-$1.75	N/A

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Unicycive Therapeutics' return on equity of -91.50% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

ARS Pharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 493.12%. Unicycive Therapeutics has a consensus target price of $18.25, indicating a potential upside of 327.90%. Given ARS Pharmaceuticals' higher possible upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

ARS Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 17 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 21 mentions for ARS Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.26 beat ARS Pharmaceuticals' score of 0.11 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Unicycive Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	19 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Unicycive Therapeutics beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Unicycive Therapeutics had 17 more articles in the media than Canopy Growth. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 21 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.26 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	14 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	19 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Canopy Growth has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market.

Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 327.90%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Unicycive Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Unicycive Therapeutics has lower revenue, but higher earnings than Canopy Growth. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.56	-$190.29M	-$0.45	N/A
Unicycive Therapeutics	$680K	174.68	-$26.56M	-$1.75	N/A

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 0.4% of Canopy Growth shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Unicycive Therapeutics beats Canopy Growth on 10 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Atea Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market.

Atea Pharmaceuticals' return on equity of -64.25% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Unicycive Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Unicycive Therapeutics	$680K	174.68	-$26.56M	-$1.75	N/A

Atea Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 37.66%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 327.90%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 38 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 38 mentions for Unicycive Therapeutics and 0 mentions for Atea Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.26 beat Atea Pharmaceuticals' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Unicycive Therapeutics	Neutral

Summary

Unicycive Therapeutics beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$126.74M	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.76%
P/E Ratio	-2.41	794.62	273.67	26.04
Price / Sales	172.83	755.06	611.82	91.49
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	2.99	10.46	10.92	6.30
Net Income	-$26.56M	$2.83B	$3.50B	$361.43M
7 Day Performance	-10.21%	-1.65%	-2.11%	-1.67%
1 Month Performance	-18.69%	-5.77%	-6.34%	-3.94%
1 Year Performance	-8.66%	-3.80%	8.81%	2.77%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	2.9285 of 5 stars	$4.22 -7.3%	$18.25 +332.5%	+2.2%	$126.74M	$680K	N/A	22	Trending News Analyst Forecast Analyst Revision
OVID Ovid Therapeutics	1.7583 of 5 stars	$2.46 -0.2%	$6.00 +144.4%	+77.4%	$477.51M	$7.25M	N/A	23	Positive News
ASMB Assembly Biosciences	2.6012 of 5 stars	$23.34 -1.2%	$47.50 +103.5%	-6.6%	$475.30M	$72.30M	22.89	73
SPRY ARS Pharmaceuticals	1.9959 of 5 stars	$4.20 +1.6%	$25.00 +495.9%	-59.2%	$417.19M	$84.28M	N/A	200	Trending News
CGC Canopy Growth	0.9496 of 5 stars	$0.93 +0.1%	N/A	-36.1%	$416.05M	$251.01M	N/A	1,128

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. OVID, ASMB, SPRY, CGC, and AVIR

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Summary

How does Unicycive Therapeutics compare to Assembly Biosciences?

Summary

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Unicycive Therapeutics compare to Canopy Growth?

Summary

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. OVID, ASMB, SPRY, CGC, and AVIR

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Do institutionals & insiders have more ownership in OVID or UNCY?

Do analysts prefer OVID or UNCY?

Is OVID or UNCY more profitable?

Which has preferable earnings & valuation, OVID or UNCY?

Which has more volatility & risk, OVID or UNCY?

Does the media favor OVID or UNCY?

Summary

How does Unicycive Therapeutics compare to Assembly Biosciences?

Do institutionals and insiders believe in ASMB or UNCY?

Which has more volatility & risk, ASMB or UNCY?

Is ASMB or UNCY more profitable?

Does the media prefer ASMB or UNCY?

Which has stronger valuation & earnings, ASMB or UNCY?

Do analysts recommend ASMB or UNCY?

Summary

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

Which has better earnings and valuation, SPRY or UNCY?

Do institutionals and insiders believe in SPRY or UNCY?

Is SPRY or UNCY more profitable?

Do analysts rate SPRY or UNCY?

Which has more risk and volatility, SPRY or UNCY?

Does the media favor SPRY or UNCY?

Summary

How does Unicycive Therapeutics compare to Canopy Growth?

Does the media prefer CGC or UNCY?

Which has more risk & volatility, CGC or UNCY?

Do analysts rate CGC or UNCY?

Is CGC or UNCY more profitable?

Which has stronger valuation and earnings, CGC or UNCY?

Do insiders and institutionals have more ownership in CGC or UNCY?

Summary

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Which has more volatility and risk, AVIR or UNCY?

Is AVIR or UNCY more profitable?

Which has preferable valuation and earnings, AVIR or UNCY?

Do analysts prefer AVIR or UNCY?

Do insiders & institutionals hold more shares of AVIR or UNCY?

Does the media prefer AVIR or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools